PKI_Waltham_Sideview_Hillside_975x594

About Us

PerkinElmer At a Glance

We are a global company committed to innovating for a healthier world. We create the instruments, tests, software and services used by scientists, researchers and clinicians to address the most critical challenges across science and healthcare.

190 countries

in operation

14,000

employees

3.8 billion

in revenue

80+ years

of innovations

DIAGNOSTICS PORTFOLIO

Driving positive outcomes through precision diagnostics

With $1.8 billion in revenue for 2020, PerkinElmer Diagnostics is a major player in the in vitro diagnostics market. Operating on a global scale, we offer innovative and complete solutions, including instruments, reagents, automation, services and software, designed to serves multiple end users and needs

RH visual

Reproductive Health

At PerkinElmer, we believe all expectant mothers should have a healthy pregnancy and all babies should have a better start in life. To do so, we provide laboratories and clinics with complete screening solutions that enable them to identify a wide range of disorders from early in the pregnancy to the first few weeks of birth.

PerkinElmer is the global leader in prenatal and newborn screening. Last year, 135 million PerkinElmer tests were used to screen babies for various disorders. To date, more than 702 million babies have been tested for life-threatening diseases using PerkinElmer’s newborn screening tools.

Rectangle 281

Immunodiagnostics

EUROIMMUN, a PerkinElmer company is a leading manufacturer of medical laboratory diagnostics worldwide and stands for innovation. The company commands extensive know-how and a broad technology base allowing in-house research, development and production to optimally meet the customer needs.

Laboratories in over 140 countries rely on our test systems as well as automation and software solutions for the diagnostics of autoimmune and infectious diseases as well as allergies, and to perform genetic analyses.

shutterstock_1148535110

Applied Genomics

PerkinElmer’s optimized, automated solutions are designed to eliminate the challenges associated with genomic and proteomic analysis by providing labs with complete, single-source solutions encompassing everything from sample to solution.

We are working closely with laboratories around the world to deliver the SARS-CoV-2 detection, screening and surveillance solutions they need, when they need them. Our nucleic acid isolation, automation, real-time PCR and NGS library preparation solutions allow labs to rapidly respond to their SARS-CoV-2 challenges with flexible, single-source workflows.

(SCIENCE) Scientists are certain activities on experimental scie

Learn more about the PerkinElmer portfolio